Shire Plc (SHPG) announced that a Phase 2 clinical trial evaluating its investigational protein replacement, SHP607, failed to achieve its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition. The study did show clinically relevant effects in secondary endpoints related to severe bronchopulmonary dysplasia (BPD) (a chronic lung disease) and severe intraventricular hemorrhage (IVH) (type of brain injury). Results showed a 53% reduction in the incidence of severe BPD and an 89% reduction in those infants who achieved a prespecified target of drug exposure. The incidence of severe IVH was reduced 44% (64% in infants who achieved the target drug exposure). Another secondary endpoint, time to discharge from neonatal intensive care, was not met.